Lupin gets Health Canada nod for plaque psoriasis treatment Rymti

Published On 2022-09-13 08:49 GMT   |   Update On 2022-09-13 08:50 GMT
Advertisement

Mumbai: Global pharma major, Lupin Limited, announced today that Health Canada has approved Rymti, its biosimilar to Enbrel (etanercept), for use in Canada.

Rymti is indicated in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis and non-radiographic axial spondyloarthritis), plaque psoriasis and paediatric plaque psoriasis.

Etanercept is an injectable, biologic medicine which inhibits Tumour Necrosis Factor (TNF). TNF is a key cytokine involved in the pro-inflammatory cascade in many chronic, immune-mediated inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis or plaque psoriasis. By specifically binding to TNF, etanercept blocks its activity, thereby reducing inflammation and other disease symptoms.

"Lupin is committed to enhancing patient access to high-quality, life-enhancing biosimilars," said Dr. Cyrus Karkaria, President, Lupin Biotech. "The approval for Rymti in Canada is a key milestone in our endeavors to improve access to medicines. It underscores the scientific success of Lupin's biosimilar programs and our commitment to advancing healthcare through innovation."

"The approval of Rymti is an important first step for Lupin's biosimilar franchise in Canada," said Dr. Sofia Mumtaz, President – Legal & Compliance and Canada, Australia, and Japan. "We believe biosimilars will provide more Canadians with access to quality treatment, while reducing healthcare costs."

Read also: Lupin unveils Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution in US

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions. The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas.

Read also: Lupin, DKSH ink pact to commercialize 5 of Alvotech proposed biosimilars in Philippines

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News